secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKWELL MEDICAL, INC. (RMTI)
CIK:        0001041024
Form:       8-K
Filed at:   2022-06-22T23:59:59+00:00
Accession:  0001104659-22-073284
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 3.02, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rockwell Medical CEO Russell Ellison steps down; Mark Strobeck appointed CEO; DaVita gets $7.5M preferred stock
--------------------------------------------------------------------------------

- CEO Russell Ellison steps down effective June 30, 2022; severance includes $500K base salary and $350K target bonus over 12 months plus option vesting extension.
- Mark Strobeck appointed President and CEO effective July 1, 2022; base salary $550K, target bonus 60%, initial time-based option grant of 400,000 shares.
- Issued additional 7,500 shares of Series X Convertible Preferred Stock to DaVita on June 16, 2022 for gross proceeds of $7.5 million (second closing under SPA).
- Dr. Strobeck also appointed to the Board as a Class III director with term through 2024 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1041024/000110465922073284/0001104659-22-073284-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1041024/000110465922073284/tm2219051d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-073284

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer